Gary L. Stump

838 total citations
25 papers, 527 citations indexed

About

Gary L. Stump is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Gary L. Stump has authored 25 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 13 papers in Molecular Biology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Gary L. Stump's work include Cardiac electrophysiology and arrhythmias (17 papers), Cardiac Arrhythmias and Treatments (14 papers) and Ion channel regulation and function (11 papers). Gary L. Stump is often cited by papers focused on Cardiac electrophysiology and arrhythmias (17 papers), Cardiac Arrhythmias and Treatments (14 papers) and Ion channel regulation and function (11 papers). Gary L. Stump collaborates with scholars based in United States and Belgium. Gary L. Stump's co-authors include Joseph J. Lynch, Christopher P. Regan, Audrey A. Wallace, Nigel J. Liverton, Stefanie A. Kane, Charles McIntyre, Douglas C. Beshore, Laszlo Kiss, Christopher J. Dinsmore and David A. Claremon and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Journal of Medicinal Chemistry.

In The Last Decade

Gary L. Stump

25 papers receiving 502 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary L. Stump United States	14	270	232	113	70	51	25	527
Christophe Pignier France	12	224 0.8×	237 1.0×	62 0.5×	97 1.4×	49 1.0×	21	476
Noriyuki Naya Japan	14	155 0.6×	230 1.0×	99 0.9×	30 0.4×	71 1.4×	30	521
Alain Le Bec France	10	210 0.8×	482 2.1×	102 0.9×	55 0.8×	175 3.4×	11	643
Robert Létienne France	11	191 0.7×	127 0.5×	62 0.5×	39 0.6×	18 0.4×	26	376
L T Hamel United States	14	169 0.6×	268 1.2×	69 0.6×	63 0.9×	178 3.5×	18	516
Cristina Zocchi Italy	14	87 0.3×	509 2.2×	220 1.9×	166 2.4×	35 0.7×	26	902
Tetsumi Hosokawa Japan	7	79 0.3×	218 0.9×	79 0.7×	49 0.7×	50 1.0×	16	496
N. Wesley Norton United States	9	58 0.2×	169 0.7×	101 0.9×	52 0.7×	62 1.2×	11	482
Marie‐Odile Guimond Canada	14	223 0.8×	277 1.2×	27 0.2×	84 1.2×	76 1.5×	20	492
Theodore P. Broten United States	13	195 0.7×	124 0.5×	122 1.1×	49 0.7×	113 2.2×	21	465

Countries citing papers authored by Gary L. Stump

Since Specialization

Citations

This map shows the geographic impact of Gary L. Stump's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary L. Stump with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary L. Stump more than expected).

Fields of papers citing papers by Gary L. Stump

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary L. Stump. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary L. Stump. The network helps show where Gary L. Stump may publish in the future.

Co-authorship network of co-authors of Gary L. Stump

This figure shows the co-authorship network connecting the top 25 collaborators of Gary L. Stump. A scholar is included among the top collaborators of Gary L. Stump based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary L. Stump. Gary L. Stump is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Regan, Christopher P., et al.. (2016). Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs. Journal of Pharmacological and Toxicological Methods. 81. 107–114. 5 indexed citations

Lynch, Joseph J., Christopher P. Regan, Gary L. Stump, et al.. (2009). Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist. Journal of Cardiovascular Pharmacology. 53(1). 52–59. 8 indexed citations

Lynch, Joseph J., Gary L. Stump, Stefanie A. Kane, & Christopher P. Regan. (2009). The Prototype Serotonin 5-HT1B/1D Agonist Sumatriptan Increases the Severity of Myocardial Ischemia During Atrial Pacing in Dogs With Coronary Artery Stenosis. Journal of Cardiovascular Pharmacology. 53(6). 474–479. 8 indexed citations

Regan, Christopher P., Gary L. Stump, Stefanie A. Kane, & Joseph J. Lynch. (2008). Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis. Journal of Pharmacology and Experimental Therapeutics. 328(2). 571–578. 24 indexed citations

Nguyen, Kevin T., Christopher F. Claiborne, John A. McCauley, et al.. (2007). Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(14). 3997–4000. 19 indexed citations

Regan, Christopher P., Gary L. Stump, Audrey A. Wallace, et al.. (2007). In Vivo Cardiac Electrophysiologic and Antiarrhythmic Effects of an Isoquinoline IKur Blocker, ISQ-1, in Rat, Dog, and Nonhuman Primate. Journal of Cardiovascular Pharmacology. 49(4). 236–245. 19 indexed citations

Regan, Christopher P., Laszlo Kiss, Gary L. Stump, et al.. (2007). Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2 H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure. Journal of Pharmacology and Experimental Therapeutics. 324(1). 322–330. 28 indexed citations

Nanda, Kausik K., Matthew J. Cato, Stefanie A. Kane, et al.. (2006). Potent antagonists of the Kv1.5 potassium channel: Synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides. Bioorganic & Medicinal Chemistry Letters. 16(22). 5897–5901. 11 indexed citations

Stump, Gary L., Audrey A. Wallace, Christopher P. Regan, & Joseph J. Lynch. (2005). In Vivo Antiarrhythmic and Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide. Journal of Pharmacology and Experimental Therapeutics. 315(3). 1362–1367. 46 indexed citations

10.

Brochu, Richard M., Ivy E. Dick, Jason Tarpley, et al.. (2005). Block of Peripheral Nerve Sodium Channels Selectively Inhibits Features of Neuropathic Pain in Rats. Molecular Pharmacology. 69(3). 823–832. 45 indexed citations

11.

Duggan, Mark E., Wasyl Halczenko, Carmen Fernández‐Metzler, et al.. (2003). Non-Peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold. Bioorganic & Medicinal Chemistry Letters. 13(10). 1809–1812. 13 indexed citations

12.

Stump, Gary L., Garry R. Smith, Andrew J. Tebben, et al.. (2003). In Vivo Canine Cardiac Electrophysiologic Profile of 1,4-Benzodiazepine Iks Blockers. Journal of Cardiovascular Pharmacology. 42(1). 105–112. 15 indexed citations

13.

Lynch, Joseph J., Joseph J. Salata, Audrey A. Wallace, et al.. (2002). Antiarrhythmic Efficacy of Combined IKs and β-Adrenergic Receptor Blockade. Journal of Pharmacology and Experimental Therapeutics. 302(1). 283–289. 7 indexed citations

14.

Stump, Gary L., et al.. (2000). Arrhythmogenic potential of positive inotropic agents. Basic Research in Cardiology. 95(3). 186–198. 28 indexed citations

15.

Lynch, Joseph J., et al.. (1999). EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. Journal of the American College of Cardiology. 34(3). 876–884. 12 indexed citations

16.

Cook, Jacquelynn J., Gary R. Sitko, Marie A. Holahan, et al.. (1997). Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.. PubMed. 96(3). 949–58. 13 indexed citations

17.

Lynch, Joseph J., et al.. (1996). Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction.. Journal of Pharmacology and Experimental Therapeutics. 277(2). 671–678. 5 indexed citations

18.

Damiano, Bruce P., Edward C. Giardino, Barbara J. Haertlein, et al.. (1994). Cardiovascular Profile of RWJ 29009, a New Potassium Channel Activator, in Anesthetized and Conscious Dogs. Journal of Cardiovascular Pharmacology. 23(2). 300–310. 6 indexed citations

19.

Damiano, Bruce P., Gary L. Stump, Wai-man Cheung, & Joseph J. Salata. (1993). In Vivo Cardiac Electrophysiologic Effects of RWJ 29009, a New Potassium-Channel Activator, in Comparison to Cromakalim and Nicardipine. Journal of Cardiovascular Pharmacology. 22(1). 143–152. 4 indexed citations

20.

Damiano, Bruce P., Gary L. Stump, & Susan K. Yagel. (1991). Investigation of Electrophysiologic Mechanisms for the Antiarrhythmic Actions of R 56865 in Cardiac Glycoside Toxicity. Journal of Cardiovascular Pharmacology. 18(3). 415–428. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact